Amy McHugh, a spokesperson for BCBS, told WBUR's John Bender that the insurance company would continue covering GLP-1 medication for subscribers with diabetes
m bo tip cn dch v chm sc trn i, ly con ngi lm trung tm: Ngi bnh bo ph cn c iu tr ton din, t t vn dinh dng, h tr tm l n dng thuc v theo di lu di
This brief duration of action limits its therapeutic utility in its natural form, necessitating the development of longer-acting GLP-1 receptor agonists that can provide sustained clinical benefits with less frequent dosing
Novo Nordisk used fresh diabetes data to bolster CagriSema ahead of a pivotal obesity decision, and separately broadened its semaglutide case beyond weight loss into wider cardiometabolic benefit
Weight loss doesnt happen linearly
Answer a few quick questions and get your free Health Optimizer Profile: your stack, spending, data obsession, and longevity focus, scored against the community